Viral Vector Based Immunotherapy for Peanut Allergy.

Area of Science:

• Immunology
• Gene Therapy
• Allergy Research

Background:

• Food allergy (FA) affects up to 10% of the population, stemming from immune system failures in tolerating dietary antigens.
• Peanut allergy is a common FA with a high risk of severe reactions like anaphylaxis.
• Current immunotherapies may not provide lasting protection, highlighting the need for novel treatments.

Purpose of the Study:

• To investigate the efficacy of liver-directed gene therapy using adeno-associated virus (AAV) vectors in treating food allergies.
• To determine if AAV-mediated gene therapy can induce antigen-specific regulatory T cells (Tregs) and prevent allergic reactions.

Main Methods:

• Utilized adeno-associated virus (AAV) vectors for liver-directed gene therapy in mouse models of food allergy.
• Administered AAV vectors expressing peanut antigens (Ara h1, Ara h2, Ara h3, Ara h6) or a single antigen (Ara h3).
• Assessed the induction of transgene product-specific Tregs, eradication of pathogenic antibodies, and protection against anaphylaxis.

Main Results:

• AAV gene therapy successfully induced antigen-specific Tregs and eradicated pre-existing pathogenic antibodies in FA models.
• Hepatic co-expression of four peanut antigens or single Ara h3 expression prevented peanut allergy development in an epicutaneous model.
• The approach demonstrated protection against anaphylaxis in ovalbumin-induced FA models.

Conclusions:

• Liver-directed AAV gene therapy is a promising strategy for inducing immune tolerance in food allergies.
• This approach may address the reduction in Treg numbers and/or function observed in FA patients.
• AAV gene therapy offers a potential therapeutic avenue for managing food allergies, including peanut allergy.